Amgen is to acquire Dezima Pharma B.V., which recently published highly positive Phase IIb data with its CETP inhibitor TA-8995 suggesting it might have potential as a more cost-effective option for lowering cholesterol than the PCSK9 inhibitor approach. Amgen just had its cholesterol-lowering injectable PCSK9 inhibitor antibody Repatha (evolocumab) approved.
Amgen acquires 'cheaper, oral' alternative to Repatha
Amgen is to acquire Dezima Pharma B.V., which recently published highly positive Phase IIb data with its CETP inhibitor TA-8995 suggesting it might have potential as a more cost-effective option for lowering cholesterol than the PCSK9 inhibitor approach. Amgen just had its cholesterol-lowering injectable PCSK9 inhibitor antibody Repatha (evolocumab) approved.